pregabalin eql pharma 150 mg kapsel, hård
eql pharma ab - pregabalin - kapsel, hård - 150 mg - pregabalin 150 mg aktiv substans; mannitol hjälpämne; propylenglykol hjälpämne
pregabalin eql pharma 300 mg kapsel, hård
eql pharma ab - pregabalin - kapsel, hård - 300 mg - propylenglykol hjälpämne; mannitol hjälpämne; pregabalin 300 mg aktiv substans
pregabalin eql pharma 75 mg kapsel, hård
eql pharma ab - pregabalin - kapsel, hård - 75 mg - pregabalin 75 mg aktiv substans; mannitol hjälpämne; propylenglykol hjälpämne
pregabalin eql pharma 200 mg kapsel, hård
eql pharma ab - pregabalin - kapsel, hård - 200 mg - propylenglykol hjälpämne; pregabalin 200 mg aktiv substans; mannitol hjälpämne
pregabalin eql pharma 25 mg kapsel, hård
eql pharma ab - pregabalin - kapsel, hård - 25 mg - propylenglykol hjälpämne; pregabalin 25 mg aktiv substans; mannitol hjälpämne
pregabalin eql pharma 50 mg kapsel, hård
eql pharma ab - pregabalin - kapsel, hård - 50 mg - propylenglykol hjälpämne; pregabalin 50 mg aktiv substans; mannitol hjälpämne
pregabalin eql pharma 100 mg kapsel, hård
eql pharma ab - pregabalin - kapsel, hård - 100 mg - propylenglykol hjälpämne; pregabalin 100 mg aktiv substans; mannitol hjälpämne
latanoprost eql pharma 50 mikrogram/ml ögondroppar, lösning
eql pharma ab - latanoprost - Ögondroppar, lösning - 50 mikrogram/ml - makrogolglycerolhydroxistearat hjälpämne; latanoprost 50 mikrog aktiv substans
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
tapentadol depot g.l. pharma 100 mg depottablett
g.l. pharma gmbh - tapentadoltartrat - depottablett - 100 mg - tapentadoltartrat 167,81 mg aktiv substans